- Home
- GLUE vs BWMX Comparison
GLUE vs BWMX Comparison
Compare GLUE & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- BWMX
- Stock Information
- Founded
- GLUE 2019
- BWMX 1995
- Country
- GLUE United States
- BWMX Mexico
- Employees
- GLUE N/A
- BWMX N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- BWMX Catalog/Specialty Distribution
- Sector
- GLUE Health Care
- BWMX Consumer Discretionary
- Exchange
- GLUE Nasdaq
- BWMX Nasdaq
- Market Cap
- GLUE 351.2M
- BWMX 495.6M
- IPO Year
- GLUE 2021
- BWMX N/A
- Fundamental
- Price
- GLUE $4.80
- BWMX $13.29
- Analyst Decision
- GLUE Buy
- BWMX Strong Buy
- Analyst Count
- GLUE 2
- BWMX 1
- Target Price
- GLUE $13.50
- BWMX $22.50
- AVG Volume (30 Days)
- GLUE 369.2K
- BWMX 55.5K
- Earning Date
- GLUE 08-07-2025
- BWMX 10-23-2025
- Dividend Yield
- GLUE N/A
- BWMX 10.75%
- EPS Growth
- GLUE N/A
- BWMX N/A
- EPS
- GLUE 0.29
- BWMX 0.84
- Revenue
- GLUE $177,986,000.00
- BWMX $751,432,052.00
- Revenue This Year
- GLUE $83.76
- BWMX $6.54
- Revenue Next Year
- GLUE N/A
- BWMX $6.09
- P/E Ratio
- GLUE $16.32
- BWMX $15.88
- Revenue Growth
- GLUE 2990.57
- BWMX 4.83
- 52 Week Low
- GLUE $3.50
- BWMX $7.00
- 52 Week High
- GLUE $12.40
- BWMX $14.46
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- BWMX 62.09
- Support Level
- GLUE $4.54
- BWMX $13.06
- Resistance Level
- GLUE $4.93
- BWMX $13.50
- Average True Range (ATR)
- GLUE 0.21
- BWMX 0.45
- MACD
- GLUE 0.06
- BWMX -0.13
- Stochastic Oscillator
- GLUE 81.43
- BWMX 66.64
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.